Sucha Asbell

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address833 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mahadevan A, Emami B, Grimm J, Kleinberg LR, Redmond KJ, Welsh JS, Rostock R, Kemmerer E, Forster KM, Stanford J, Shah S, Asbell SO, LaCouture TA, Scofield C, Butterwick I, Xue J, Muacevic A, Adler JR. Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models. Front Oncol. 2020; 10:591430. PMID: 33634020.
      Citations:    
    2. Xu Q, Fan J, Grimm J, LaCouture T, Asbell S, Park JH, Kubicek G. The dosimetric impact of the prescription isodose line (IDL) on the quality of robotic stereotactic radiosurgery (SRS) plans. Med Phys. 2017 Dec; 44(12):6159-6165. PMID: 29064585.
      Citations:    
    3. Peterson J, Niles C, Patel A, Boujaoude Z, Abouzgheib W, Goldsmith B, Asbell S, Xu Q, Khrizman P, Kubicek GJ. Stereotactic Body Radiotherapy for Large (> 5 cm) Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 07; 18(4):396-400. PMID: 28040379.
      Citations:    
    4. Xue J, Kubicek G, Patel A, Goldsmith B, Asbell SO, LaCouture TA. Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels. Semin Radiat Oncol. 2016 Apr; 26(2):135-9. PMID: 27000510.
      Citations:    
    5. LaCouture TA, Xue J, Subedi G, Xu Q, Lee JT, Kubicek G, Asbell SO. Small Bowel Dose Tolerance for Stereotactic Body Radiation Therapy. Semin Radiat Oncol. 2016 Apr; 26(2):157-64. PMID: 27000513.
      Citations:    
    6. Asbell SO, Grimm J, Xue J, Chew MS, LaCouture TA. Introduction and Clinical Overview of the DVH Risk Map. Semin Radiat Oncol. 2016 Apr; 26(2):89-96. PMID: 27000504.
      Citations:    
    7. Subedi G, Karasick T, Grimm J, Jain S, Xue J, Xu Q, Chen Y, Asbell S, Pahlajani N, LaCouture T. Factors that may determine the targeting accuracy of image-guided radiosurgery. Med Phys. 2015 Oct; 42(10):6004-10. PMID: 26429275.
      Citations:    
    8. Xu Q, Hanna G, Grimm J, Kubicek G, Pahlajani N, Asbell S, Fan J, Chen Y, LaCouture T. Quantifying rigid and nonrigid motion of liver tumors during stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Sep 01; 90(1):94-101. PMID: 25195990.
      Citations:    
    9. Kubicek GJ, Xue J, Xu Q, Asbell SO, Hughes L, Kramer N, Youssef A, Chen Y, Aikens J, Saul H, Pahlajani N, LaCouture T. Stereotactic body radiotherapy as an alternative to brachytherapy in gynecologic cancer. Biomed Res Int. 2013; 2013:898953. PMID: 24000329.
      Citations:    
    10. Srivastava R, Asbell SO, Lacouture T, Kramer N, Pahlajani N, Xue J, Ahmad N, Chen Y, Croce R, Grimm J. Low toxicity for lung tumors near the mediastinum treated with stereotactic body radiation therapy. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):130-7. PMID: 24674316.
      Citations:    
    11. Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU, Sandler HM. The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02. Clin Cancer Res. 2009 Sep 01; 15(17):5478-84. PMID: 19706804.
      Citations:    
    12. Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):672-8. PMID: 18990504.
      Citations:    
    13. Chakravarti A, DeSilvio M, Zhang M, Grignon D, Rosenthal S, Asbell SO, Hanks G, Sandler HM, Khor LY, Pollack A, Shipley W. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol. 2007 Jul 20; 25(21):3082-9. PMID: 17634487.
      Citations:    
    14. Lawton CA, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):646-55. PMID: 17531401.
      Citations:    
    15. Small W, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, Erickson B, Jhingran A, Greven K. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1081-7. PMID: 17398031.
      Citations:    
    16. Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR, Shipley WU. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):647-53. PMID: 17011443.
      Citations:    
    17. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005 Apr 01; 61(5):1285-90. PMID: 15817329.
      Citations:    
    18. Emami B, Mirkovic N, Scott C, Byhardt R, Graham MV, James Andras E, John M, Herskovic A, Urtasun R, Asbell SO, Perez CA, Cox J. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer. 2003 Aug; 41(2):207-14. PMID: 12871784.
      Citations:    
    19. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003 Jan; 169(1):245-50. PMID: 12478146.
      Citations:    
    Asbell's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (103)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _